Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hye-Ryoun | - |
dc.contributor.author | Lee, Sung Yong | - |
dc.contributor.author | Hyun, Dae-Sung | - |
dc.contributor.author | Lee, Min Ki | - |
dc.contributor.author | Lee, Hyun-Kyung | - |
dc.contributor.author | Choi, Chang-Min | - |
dc.contributor.author | Yang, Sei-Hoon | - |
dc.contributor.author | Kim, Young-Chul | - |
dc.contributor.author | Lee, Yong Chul | - |
dc.contributor.author | Kim, Sun Young | - |
dc.contributor.author | Jang, Seung Hun | - |
dc.contributor.author | Lee, Jae Cheol | - |
dc.contributor.author | Lee, Kye Young | - |
dc.date.available | 2020-11-02T20:45:21Z | - |
dc.date.issued | 2013-08-09 | - |
dc.identifier.issn | 1756-9966 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/10463 | - |
dc.description.abstract | Background: Epidermal growth factor receptor (EGFR)-activating mutations are major determinants in predicting the tumor response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). Noninvasive test for the detection of EGFR mutations is required, especially in NSCLC patients from whom tissue is not available. In this study, we assessed the feasibility of detection of EGFR mutations in free DNA circulating in plasma. Methods: Plasma samples of 60 patients with partial response to gefitinib were analyzed to detect EGFR-activating mutations in exons 19 and 21. Forty (66.7%) of patients had tumor EGFR mutation results. EGFR mutations in plasma were detected using the peptide nucleic acid (PNA)-mediated polymerase chain reaction (PCR) clamping method. All clinical data and plasma samples were obtained from 11 centers of the Korean Molecular Lung Cancer Group (KMLCG). Results: Of the 60 patients, 39 were female and the median age was 62.5 years. Forty-three patients never smoked, 53 had adenocarcinomas, and seven had other histologic types. EGFR-activating mutation was detected in plasma of 10 cases (exon 19 deletion in seven and exon 21 L858R point mutation in three). It could not be found in plasma after treatment for 2 months. When only patients with confirmed EGFR mutation in tumor were analyzed, 17% (6 of 35) of them showed positive plasma EGFR mutation and the mutation type was completely matched with that in tumor. There was no statistically significant difference in clinical parameters between patients with EGFR mutations in plasma and those without EGFR mutations. Conclusions: The detection rate of EGFR mutations from plasma was not so high despite highly sensitive EGFR mutation test suggesting that more advances in detection methods and further exploration of characteristics of circulating free DNA are required. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BMC | - |
dc.title | Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1186/1756-9966-32-50 | - |
dc.identifier.scopusid | 2-s2.0-84881137132 | - |
dc.identifier.wosid | 000323129700001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, v.32 | - |
dc.citation.title | JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | - |
dc.citation.volume | 32 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | POLYMERASE-CHAIN-REACTION | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITORS | - |
dc.subject.keywordPlus | RAPID DETECTION | - |
dc.subject.keywordPlus | PLASMA DNA | - |
dc.subject.keywordPlus | CHINESE PATIENTS | - |
dc.subject.keywordPlus | GENE-MUTATIONS | - |
dc.subject.keywordPlus | GEFITINIB | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordAuthor | Plasma | - |
dc.subject.keywordAuthor | EGFR mutation | - |
dc.subject.keywordAuthor | PNA-mediated PCR clamping method | - |
dc.subject.keywordAuthor | Non-small cell lung cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.